Allianz Asset Management AG decreased its stake in shares of AAC Holdings Inc (NYSE:AAC) by 88.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,512 shares of the company’s stock after selling 355,032 shares during the period. Allianz Asset Management AG owned 0.20% of AAC Holdings worth $344,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV acquired a new position in AAC Holdings during the fourth quarter valued at about $115,000. Mizuho Securities USA Inc. purchased a new stake in AAC Holdings during the third quarter valued at $174,000. Dynamic Technology Lab Private Ltd purchased a new stake in AAC Holdings during the fourth quarter valued at $216,000. Marshall Wace LLP boosted its stake in AAC Holdings by 26.9% in the fourth quarter. Marshall Wace LLP now owns 35,133 shares of the company’s stock valued at $254,000 after buying an additional 7,443 shares during the period. Finally, Monarch Partners Asset Management LLC purchased a new stake in AAC Holdings during the third quarter valued at $350,000. 44.14% of the stock is owned by hedge funds and other institutional investors.
AAC Holdings Inc (NYSE:AAC) traded down 2.25% on Friday, hitting $7.39. 86,580 shares of the company were exchanged. The stock’s market capitalization is $175.07 million. The company has a 50 day moving average price of $8.33 and a 200-day moving average price of $9.59. AAC Holdings Inc has a 52 week low of $6.01 and a 52 week high of $24.38.
Separately, Zacks Investment Research cut shares of AAC Holdings from a “hold” rating to a “sell” rating in a report on Thursday, March 2nd. Four analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $23.25.
About AAC Holdings
AAC Holdings, Inc is a provider of inpatient and outpatient substance abuse treatment services for individuals with drug and alcohol addiction. The Company performs drug testing and diagnostics laboratory services and provides physician services to its clients. As of June 30, 2016, the Company operated 12 residential substance abuse treatment facilities located throughout the United States, focused on delivering clinical care and treatment solutions across 1,139 beds, which includes 636 licensed detoxification beds, and 18 standalone outpatient centers.
